Navigation Links
Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging,Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- Alfacell Corporation today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference in New York.

The audio and slide presentation will be available live at http://www.wsw.com/webcast/ceut6/acel.ob/. A replay will be available at this address within 24 hours of the presentation and will be archived for 90 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:

    David Schull or Wendy Lau           Andreas Marathovouniotis

    Russo Partners                      Russo Partners

    212-845-4271                        212-845-4253

       

    

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com wendy.lau@russopartnersllc.com

CONTACT: Media: David Schull, , or WendyLau, , +1-212-845-4271, or Investors: AndreasMarathovouniotis, , +1-212-845- 4253,all of Russo Partners for Alfacell Corporation david.schull@russopartnersllc.com wendy.lau@russopartnersllc.com andreas.marathis@russopartnersllc.com

Web site: http://www.alfacell.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
8. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
9. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
10. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
11. The Past, Present and Future of HLA Typing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... YORK , Feb. 27, 2017 /PRNewswire/ ... Michael P. Vallely , MBBS, PhD, FRACS, of  ... University of Sydney will be published ...  Journal of the American College of Cardiology ... "no-touch" beating heart bypass surgery technique (anOPCABG) ...
(Date:2/27/2017)... Feb. 27, 2017  International Biophysics Corporation, a global medical ... today announced a 34% revenue growth in 2016 when compared ... unit sales.  This growth was fueled by its AffloVest® sales ... to the expansion of its global sales of surgical product ... CEO, "As we enter our 25 th year in ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... for RGN-137, GtreeBNT Co., Ltd., received a positive ... 3 clinical trial design for RGN-137 to treat ... healing gel that incorporates Thymosin beta 4 ("Tß4") ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had ... his impoverished upbringing and life experiences could have led him down a much different ... Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Much attention has ... for women who become dependent on opioid painkillers has fallen short. From 1999 until ... to a 237% increase in fatal overdoses in male populations.(1) , The proportion of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. ... studying to become a nun. Now, she writes about God, when she isn’t swimming as ... BC and AD, Here is BS! (Before Satan),” she offers a comedic look at the ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
Breaking Medicine News(10 mins):